New TB cocktail shows promise in early trial

NCT ID NCT04550832

First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 30 times

Summary

This study tested a new drug called delpazolid, given with three standard TB medicines, to see if it is safe and works better than the standard drugs alone. 76 adults with newly diagnosed, drug-sensitive tuberculosis took part. The goal was to find the best dose and understand how the body processes the drug, aiming to improve TB control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical HIV Research Unit (CHRU) University of the Witwatersrand

    Johannesburg, 2092, South Africa

  • Ifakara Health Institute

    Bagamoyo, Tanzania

  • Ki'bongoto Infectious Disease Hospital (KIDH) Kilimanjaro Clinical Research Institute (KCRI)

    Moshi, Tanzania

  • National Institute for Medical Research (NIMR-MMRC)

    Mbeya, Tanzania

  • The Aurum Institute Tembisa Clinical Research Centre

    Tembisa, Gauteng, 1632, South Africa

Conditions

Explore the condition pages connected to this study.